
Opinion|Videos|November 22, 2023
Factors Informing Individualized Treatment Decision-Making for HER2-Positive Metastatic Breast Cancer
Author(s)Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH explains that treatment decisions for metastatic breast cancer are based on the current biopsy showing receptor status, but prior biopsies over the full course of disease are considered as well, particularly for HER2 targeted therapies which may work even if HER2 low expression occurred years earlier.
Advertisement
Episodes in this series

Advertisement
Related to this article

The FDA approved Wilserdly with everolimus for some ER-positive, HER2-negative, ESR1-mutated advanced breast cancers that grew after prior hormone therapy.

City of Hope experts share integrative therapies that may ease breast cancer side effects such as joint pain, hot flashes, poor sleep, fatigue and anxiety.

City of Hope experts explain integrative oncology in breast cancer: when to consider it, why it won't replace treatment and what to know about supplements.

A mother whose daughter is seven years past breast cancer treatment shares how scan anxiety and waiting shape life after cancer for survivors and families.

A review of 29 studies in more than 22,000 women 65 and older with ER-positive breast cancer found no statistically significant survival difference between hormone therapy alone and surgery first, though surgery controlled the cancer in the breast better.

A 12-year breast cancer survivor with 16 tattoos, including radiation marks, weighs new research on tattoos and lymphoma risk and the questions it prompts.

Dr. Rebecca Dent explains how Datroway kept brain metastases in check longer than chemotherapy in triple-negative breast cancer, and what patients should know.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Wilserdly Combo for ESR1-Mutated Breast Cancer
2
Breast Cancer Side Effects: Integrative Therapies That May Help
3
5 Ways to Handle Thanksgiving During Cancer Treatment
4
5 Things to Know About Shorter Radiation for Prostate Cancer
5

